share_log

賽生藥業：根據收購守則規則3.8刊發的公告

SCICLONE PHARMA: ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

Hong Kong Stock Exchange ·  Apr 18 10:50
Summary by Moomoo AI
賽生藥業控股有限公司於2024年4月18日發布公告，提及Silver Pegasus Investment Limited建議私有化的聯合公告，以及公司多項購股權計劃的最新進展。公告指出，根據2018年批准的購股權激勵計劃及2021年股東決議案採納的首次公開發售後購股權計劃，共有7,167,360份購股權已歸屬，706,840份購股權失效，以及180,000份購股權已被行使。此外，公司已發行新股份180,000股，使得總發行股份達到628,323,532股。賽生藥業亦披露了目前購股權的狀況，包括購股權激勵計劃及首次公開發售後購股權計劃下的未行使購股權。公司強調，除已披露外，無其他未行使的證券、購股權或衍生工具。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告內容無遺漏事實，不會導致誤導。股東及潛在投資者應謹慎行事，並在必要時尋求專業意見。
賽生藥業控股有限公司於2024年4月18日發布公告，提及Silver Pegasus Investment Limited建議私有化的聯合公告，以及公司多項購股權計劃的最新進展。公告指出，根據2018年批准的購股權激勵計劃及2021年股東決議案採納的首次公開發售後購股權計劃，共有7,167,360份購股權已歸屬，706,840份購股權失效，以及180,000份購股權已被行使。此外，公司已發行新股份180,000股，使得總發行股份達到628,323,532股。賽生藥業亦披露了目前購股權的狀況，包括購股權激勵計劃及首次公開發售後購股權計劃下的未行使購股權。公司強調，除已披露外，無其他未行使的證券、購股權或衍生工具。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告內容無遺漏事實，不會導致誤導。股東及潛在投資者應謹慎行事，並在必要時尋求專業意見。
Sesong Pharmaceutical Holdings Limited issued a notice on 18 April 2024, mentioning the joint announcement of the proposed privatization of Silver Pegasus Investment Limited and the latest progress of the company's multiple share option plans. The announcement noted that under the Share Option Incentive Plan approved in 2018 and the Initial Public Offering Possession Option Plan adopted in 2021, a total of 7,167,360 call options have been vested, 706,840 call options have expired and 180,000 shares have been exercised. In addition, the company has issued 180,000 shares of new shares, bringing the total issued share to 628,323,532 shares. CAYSON PHARMACEUTICALS ALSO DISCLOSED THE CURRENT STATUS OF SHARE OPTIONS, INCLUDING UNEXERCISED SHARE OPTIONS UNDER THE SHARE OPTION INCENTIVE SCHEME AND THE INITIAL PUBLIC OFFERING POST-IPO SHARE OPTION SCHEME...Show More
Sesong Pharmaceutical Holdings Limited issued a notice on 18 April 2024, mentioning the joint announcement of the proposed privatization of Silver Pegasus Investment Limited and the latest progress of the company's multiple share option plans. The announcement noted that under the Share Option Incentive Plan approved in 2018 and the Initial Public Offering Possession Option Plan adopted in 2021, a total of 7,167,360 call options have been vested, 706,840 call options have expired and 180,000 shares have been exercised. In addition, the company has issued 180,000 shares of new shares, bringing the total issued share to 628,323,532 shares. CAYSON PHARMACEUTICALS ALSO DISCLOSED THE CURRENT STATUS OF SHARE OPTIONS, INCLUDING UNEXERCISED SHARE OPTIONS UNDER THE SHARE OPTION INCENTIVE SCHEME AND THE INITIAL PUBLIC OFFERING POST-IPO SHARE OPTION SCHEME. The Company emphasizes that there are no other unexercised securities, call options or derivatives other than disclosed. The Board is responsible for the accuracy of the contents of the announcement and verifies that, after reasonable enquiries, the contents of the announcement are free from omissions and will not lead to misrepresentation. Shareholders and potential investors should exercise caution and seek professional advice when necessary.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more